Melatonin and Adiponectin in Hypertensive Kidney Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00498576
Recruitment Status : Completed
First Posted : July 10, 2007
Last Update Posted : June 30, 2009
Information provided by:
Sheba Medical Center

Brief Summary:

Recently we have shown that melatonin secretion is impaired in rats with metabolic syndrome. We have also demonstrated that exogenic melatonin supplementation can improve blood pressure profile in nondipper patients.

The aim of this study is to find whether there is a difference between melatonin secretion in hypertensive kidney recipients versus "normal" hypertensive patients. Secondly, to ask if there is any correlation between melatonin secretion and adiponectin levels.

Condition or disease
Hypertension Kidney Transplant

Study Type : Observational
Estimated Enrollment : 60 participants
Observational Model: Case Control
Time Perspective: Prospective
Study Start Date : September 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Melatonin

kidney transplant with hypertension
hypertensive patients with native kidneys
healthy controls

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
group1- patients from the kidney transplant unit, sheba medical center group2- patients from hypertension unit,sheba medical center

Inclusion Criteria:

  • hypertension
  • kidney transplantation ( group 1)
  • good renal function

Exclusion Criteria:

  • diabetes mellitus
  • cancer
  • renal failure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00498576

Sheba Medical Center
Ramat-gan, Israel
Sponsors and Collaborators
Sheba Medical Center
Principal Investigator: Avshalom Leibowitz, MD

Responsible Party: leibowitz avshalom, Sheba Medical Center Identifier: NCT00498576     History of Changes
Other Study ID Numbers: SHEBA-07-4730-AL-CTIL
First Posted: July 10, 2007    Key Record Dates
Last Update Posted: June 30, 2009
Last Verified: June 2009

Keywords provided by Sheba Medical Center:
kidney transplant

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Central Nervous System Depressants